Baseline inflammation as a supportive care risk marker for unplanned hospitalization during systemic therapy in patients with solid tumors

Cancer treatment often feels like a high-stakes balancing act. Doctors must deliver powerful drugs designed to destroy tumors, but these same medicines can sometimes overwhelm the body, causing severe side effects that send patients back to the hospital. For those receiving systemic therapy—treatments that travel through the bloodstream to reach cancer cells anywhere in the body—unplanned hospitalization is a major concern. It disrupts life, strains healthcare resources, and signals that a patient's body may not be tolerating the treatment well. To prevent this, clinicians usually look at standard factors like a patient's age, existing health conditions, and kidney function to guess who might struggle. However, these traditional checks sometimes miss a crucial biological signal: the body's underlying state of inflammation. Inflammation is the body's natural response to injury or infection, but when it is chronically high before treatment even begins, it can indicate that a patient is more vulnerable to the stress of chemotherapy. Researchers have long known that certain blood cells, specifically those involved in fighting infection and those that regulate the immune system, can tell a story about a patient's resilience. By looking at the ratio of these cells, doctors might be able to spot hidden risks before the first dose is ever administered.

A team of researchers at the Instituto Mexicano del Seguro Social in Ciudad Juárez set out to test whether these simple blood markers could predict who would end up in the hospital unexpectedly during the first few months of cancer treatment. They focused on two specific measurements derived from a standard blood test: the ratio of neutrophils to lymphocytes, and a broader index that also includes platelet counts. Neutrophils are white blood cells that rush to sites of infection, while lymphocytes are the cells that help the body remember and fight off diseases. When a person has too many neutrophils and too few lymphocytes, it suggests their immune system is under stress. The researchers defined "high" inflammation as a neutrophil-to-lymphocyte ratio greater than three, and a systemic immune-inflammation index greater than eight hundred. They followed ninety-four adults with solid tumors, such as breast, gastrointestinal, or gynecologic cancers, as they began their systemic therapy. The goal was to see if patients starting with these high inflammation levels were more likely to be admitted to the hospital for any reason during their first four treatment cycles.

The study revealed a clear and striking pattern. Among the entire group, about twelve percent of patients were hospitalized unexpectedly. However, when the researchers looked closer at the blood test results, the risk was not evenly distributed. Patients who started with high inflammation markers were far more likely to end up in the hospital. Specifically, nearly thirty-one percent of those with a high neutrophil-to-lymphocyte ratio were hospitalized, compared to only about six percent of those with lower levels. A similar gap appeared for the broader inflammation index: twenty-eight percent of patients with high scores were admitted, versus roughly six percent of those with lower scores. The data suggested that a patient with high baseline inflammation was roughly five times more likely to face an unplanned hospitalization than a patient with normal levels. This association held true even when the researchers accounted for age, suggesting that the inflammation itself was a strong indicator of vulnerability, independent of how old the patient was.

The researchers also investigated whether these blood markers could predict a wider range of problems, such as severe toxicity, significant weight loss, or the need to delay or reduce treatment doses. Here, the results were more nuanced. While high inflammation strongly predicted hospitalization, it did not show a statistically significant link to the broader mix of complications. The only other specific outcome that showed a connection was significant weight loss; patients with high inflammation scores were more likely to lose at least five percent of their body weight. This suggests that while these markers are excellent at flagging the risk of acute, severe decompensation requiring hospital care, they may not be as useful for predicting every type of treatment side effect. The study also noted that the specific cutoffs used—three for the ratio and eight hundred for the index—were chosen for this investigation and are not yet proven as universal rules for all patients.

Importantly, the authors emphasize that these findings are exploratory. The study was retrospective, meaning the researchers looked back at medical records rather than following patients forward in a controlled experiment, and the number of hospitalizations was relatively small. Because of this, the results should be viewed as a promising signal rather than a definitive rule. The researchers do not suggest that doctors should stop giving treatment to patients with high inflammation or change the drug dosage based solely on these numbers. Instead, they propose that these inexpensive, readily available blood tests could serve as an early warning system. If a patient shows high inflammation before starting therapy, they might benefit from closer monitoring, more frequent check-ins, or proactive support to catch problems early. By identifying these vulnerable individuals, healthcare teams could potentially intervene before a minor issue spirals into a crisis that requires a hospital bed. The study concludes that while more research is needed to confirm these findings, looking at the body's baseline inflammatory state offers a practical, low-cost way to improve safety and support for people undergoing cancer treatment.